tbuckley/cabot-search huggingface dataset:
Use of online survivorship care plans by young adult cancer survivors: Patient characteristics and patient reported outcomes.
Authors: Dava Szalda, Marilyn M. Schapira, Linda A. Jacobs, Carolyn Vachani, James M. Metz, Christine E. Hill-Kayser
Journal: Journal of Clinical Oncology (2016)

55 Background: Young adult survivors (YAS) are at risk for side effects of cancer therapy and poor post treatment self-management relative to older adult survivors (AS). Survivorship care plans (SCPs) have proved feasible to provide education on symptom management, but the characteristics of YAS who utilize SCPs and patient-reported outcomes (PROs) of YAS via SCPs remains unstudied. Methods: Patient-reported characteristics and outcomes of YAS, age 18 to 39 years, who used a free online SCP generator (OncoLife), between May 2010 and May 2012 are reported. PROs of YAS were compared to AS, age 40-70 years, via frequencies and chi-squared analyses. PROs were queried upon generation of SCP based on diagnosis and treatments received. Results: YAS (n = 1,445, M age = 31.5 years) and AS (n = 6301, M age = 56.3 years) were primarily female (69% vs. 78%), Caucasian (76% vs. 86%) and an average of 2.6 years (range 0-20years) vs. 3.2 years (range 0-46 years) since diagnosis and treatment. Most common diagnoses were breast cancer, testicular cancer, lymphoma, thyroid cancer, and sarcomas in YAS vs. breast, colon, lymphoma, prostate, and lung cancer in AS. Three-quarters (75%) of YAS and 70% of AS generated the SCP themselves with the remaining SCPs generated by health care providers. Less than a quarter (22%) of YAS or AS (18%) reported previously receiving a treatment summary. The most commonly endorsed PROs in YAS and AS were neurocognitive changes and fatigue. Fewer YAS than AS endorsed pulmonary concerns and male sexual side effects. The majority of PROs were reported at similar proportions by YAS and AS (see table). Conclusions: In patients who generated an OncoLife SCP, YAS reported similar rates of treatment-related side effects to those reported by AS demonstrating SCPs as a mechanism to capture and address off-therapy issues for all survivors. [Table: see text]
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload.
Authors: Emanuele Angelucci, David Bowen, Silvia M.M. Magalhães, Tomasz Lawniczek, Shyanne Douma, Peter Jakobs, Guillermo Garcia-Manero
Journal: Blood (2009)
Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer
Authors: R. Ramlau, M. Thomas, R. Plummer, M. Reck, C. P. Heussel, M. Lau, R. Parikh, T. Kaneko, C. Oliva, S. Novello
Journal: Journal of Clinical Oncology (2009)

e19027 Background: Lapatinib is an oral, reversible small-molecule inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR overexpression is very common in non-small-cell lung cancer (NSCLC), ranging from 30% to 83%, whereas HER2 overexpression occurs in about 20%. Pemetrexed is currently given as second-line therapy and achieves a 9% response rate. The rationale for EGFR/HER2 inhibition in combination with pemetrexed is to demonstrate clinical synergy as previously shown with gemcitabine, another fluoropyrimidine pathway inhibitor. Methods: Eligible patients included those with stage IIIB or IV NSCLC and European Cooperative Oncology Group performance status of 0–2 following 1 previous chemotherapy treatment. Patients were treated in 3 escalating dose levels (DLs) of pemetrexed (given intravenously every 21 days) and daily lapatinib (DL 0: 400 mg/1,250 mg; DL 1: 500 mg/1,250 mg; DL 2: 500 mg/1,500 mg, respectively). A standard phase 1, 3+3 trial design was used. The primary objective was to determine the optimal treatment regimen. Results: Eighteen patients were treated (DL 0: n=4, DL 1: n=8; DL 2: n=6). The most common adverse events (any grade) were diarrhea (61%), rash (44%), fatigue (28%), nausea (28%), anemia (28%), anorexia (22%), vomiting (22%), dyspnea (17%), and neutropenia (17%). Grade 3/4 adverse events were lymphocytopenia (n=5) and neutropenia (n=5). Other related grade 3 events were diarrhea (n=2), nausea (n=1), decreased ejection fraction (n=1), and increased alkaline phosphatase (n=1). The optimal treatment regimen was determined as lapatinib 1250 mg given with 500 mg pemetrexed after occurrence of 3 dose-limiting toxicities during the first cycle in DL 2 (grade 3 diarrhea, grade 4 lymphocytopenia, and grade 3 mucositis). No further dose-limiting toxicities were observed in DL 0 or DL 1. Preliminary evidence of clinical activity was encouraging, with 3 patients showing partial response. Conclusions: The combination of lapatinib with pemetrexed is well tolerated; encouraging activity has been demonstrated in pretreated NSCLC patients and warrants further studies. [Table: see text]
Clinical implication of PIK3CA activating mutation in ER + HER2+ breast cancer: Based upon explorative mutational analysis of Neo-ALL-IN study
Authors: J.H. Park, D.-H. Kim, J.-H. Ahn, J.E. Kim, K.H. Jung, G. Gong, S.-H. Ahn, H.J. Lee, B.-H. Son, H.-H. Kim, H.J. Shin, D.-H. Moon, S.-M. Ahn, S.-B. Kim
Journal: Annals of Oncology (2016)
Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study
Authors: I.-T. Wu, T.-H. Hu, C.-H. Hung, S.-N. Lu, J.-H. Wang, C.-M. Lee, C.-H. Chen
Journal: Clinical Microbiology and Infection (2017)
Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi
Authors: Carlo Visco, Annalisa Chiappella, Luca Nassi, Caterina Patti, Simone Ferrero, Daniela Barbero, Andrea Evangelista, Michele Spina, Anna Lia Molinari, Luigi Rigacci, Monica Tani, Alice Di Rocco, Graziella Pinotti, Alberto Fabbri, Renato Zambello, Silvia Finotto, Manuel Gotti, Angelo Michele Carella, Flavia Salvi, Stefano A Pileri, Marco Ladetto, Giovannino Ciccone, Gianluca Gaidano, Marco Ruggeri, Maurizio Martelli, Umberto Vitolo
Journal: Blood (2016)
Generation of Leukemia-Derived Dendritic Cells (DCleu) as a Basis for Specific Immunotherapy in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Authors: Helga Schmetzer, Christoph Schmid, Susanne Kufner, Renate Pelka-Fleischer, Tanja Kroell, Horst Zitzelsberger, Paco de Valle, W. Treder, Helmut Salih, Hans-Jochem Kolb
Journal: Blood (2004)
Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model
Authors: Johnnie J. Orozco, Aimee Kenoyer, Ethan R. Balkin, Donald K. Hamlin, D Scott Wilbur, Darrell R. Fisher, Shani L. Frayo, Mark D. Hylarides, Damian J. Green, Ajay K. Gopal, Paul O'Donnell, Oliver W. Press, John M. Pagel
Journal: Blood (2012)
Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)
Authors: Albrecht Reichle, Christina Hart, Matthias Grube, Reinhard Andreesen
Journal: Blood (2012)
Graft-Versus Host Disease (GVHD) and Infectious Complications Following Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults.
Authors: Sabine Furst, Mohamad Mohty, Catherine Faucher, Jean El-Cheikh, Patrick Ladaique, Claude Lemarie, Norbert Vey, Reda Bouabdallah, Anne-Marie Stoppa, Nicolas Marchetti, Christian Chabannon, Didier Blaise
Journal: Blood (2007)
How Much Does the Asthma Outcome Definition Matter?
Authors: Cynthia M. Visness, Agustin Calatroni, Katy F. Jaffee, George T. O'Connor, Leonard B. Bacharier, Meyer Kattan, Robert A. Wood, Peter J. Gergen, James E. Gern
Journal: Journal of Allergy and Clinical Immunology (2017)
RARE-51. PLEOMORPHIC XANTHOASTROCYTOMA OF THE CEREBELLUM IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I: A CASE REPORT AND LITERATURE REVIEW
Authors: Juanita Garces, Mansour Mathkour, Tyler Scullen, Lauren Boehm, Joshua Hanna, Olawale A.R. Sulaiman, Marcus Ware
Journal: Neuro-Oncology (2016)

Pleomorphic Xanthoastrocytoma (PXA) describes a relatively rare and often focal glioma. Lesions are preferentially supratentorial and superficially located, although cerebellar and spinal cord masses have been described. PXAs are per their name pleomorphic in nature, with a characteristic histology of neoplastic lipid containing astrocytes dispersed amongst a dense reticulin network with rare or absent mitotic figures. Surgical excision carries a favorable prognosis. Reportedly, PXA may be associated with Neurofibromatosis Type I (NF1), although such tumors are not a hallmark of the classic phenotype. In this report we describe a case of newly diagnosed cerebellar PXA in a patient with a history of NF1. A 30-year-old male with a past history of NF1 presented with complaints of somnolence, slurred speech, ataxia, urinary incontinence and nausea. Magnetic resonance imaging (MRI) was significant for an expansile heterogeneous vermian mass suspicious for medulloblastoma with 4th ventricular compression, tonsillar herniation, and moderate obstructive hydrocephalus. The patient underwent a staged suboccipital craniectomy and C1 laminectomy for posterior fossa decompression and tumor resection. Histopathology confirmed a low-grade variable neoplasm consistent with PXA. At 1 year post-surgery, the patient returned with suspected recurrence, and underwent gamma knife therapy. The patient has been recurrence free for three years. To the best of our knowledge, there are 18 prior reported cases in the literature of infratentorial PXA and 4 reports of such cases occurring in individuals with NF1. These lesions present similarly to dysplastic tumor types, and should be considered as a rare etiology of NF1 associated cerebellar masses.
Analysis of biomarkers in a pilot study of pertuzumab, trastuzumab and eribulin for advanced HER2 positive breast cancer
Authors: Yasutaka Tono, Mikiya Ishihara, Yoshihiro Miyahara, Hiroaki Ikeda, Hiroshi Shiku, Taizo Shiraishi, Toshiro Mizuno, Naoyuki Katayama
Journal: Annals of Oncology (2016)
EBV Related Lymphoproliferative Disorders Post Allogeneic Bone Marrow Transplantation for Haematological Malignancies
Authors: A. Paisiou, C. M. Vadikolia, K. Stefanaki, E. Goussetis, I. Peristeri, K. Zisaki, G. Avgerinou, G. Vessalas, V. Kitra, S. Grafakos
Journal: Blood (2015)
The outcome of definitive or salvage radiotherapy for locally advanced hepatocellular carcinoma: A retrospective cohort study of 822 patients from a single institution.
Authors: J. Seong
Journal: Journal of Clinical Oncology (2011)

248 Background: With technological development and awareness of efficacy, radiotherapy (RT) is more frequently adopted in management of hepatocellular carcinoma (HCC). To assess the efficacy of RT, we conducted this retrospective cohort study from a single institute. Methods: The analysis involved 822 patients who underwent definitive or salvage RT for locally advanced HCC from January 1997 to August 2009. Two-dimensional RT, 3-dimensional conformal RT (3D-CRT), and intensity-modulated RT including tomotherapy (IMRT) were carried out for 186 (22.6%), 579 (70.4%), and 57 (6.9%) patients, respectively. In a majority of patients, RT was done either concurrently with intra-arterial 5-FU (500 mg/m 2 ) chemotherapy (CCRT group; 326 patients, 39.7%), or following transarterial chemoembolization (TACE+RT group; 244 patients, 29.7%). Total radiation dose was 30 to 64.8 Gy (median dose 45 Gy) in 1.8-2 Gy fraction. Results: The median age of total 822 patients was 55 and 84.3% was male. The 2, 3, and 4-year overall survival rates of total patients were 21.2, 13.1, and 10.1%, respectively. In 2-year survival, the patients with Child-Pugh class A did better than B or C (23% vs 10.9%, p&lt;0.001), without portal vein thrombosis (PVT) did better than with PVT (26.8% vs 14.3%, p&lt;0.001), and without lymph node metastasis (LNM) did better than with LNM (22.9% vs 11.7%, p&lt;0.001). Patients with total dose higher than 45 Gy did better than those with less than 45 Gy (30.1% vs. 15.6%, p&lt;0.001). The best outcome was shown in patients received higher than 45 Gy using 3D-CRT or IMRT, with 2-year overall survival rates of 25.9% (CCRT) and 41.3% (TACE+RT). Conclusions: This study showed a substantial effect of RT in locally advanced HCC. Further analysis will be continued to provide the best option of radiotherapy for locally advanced HCC. No significant financial relationships to disclose.
SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC).
Authors: Jeffrey Warren Allen, James Moon, Shirish M. Gadgeel, Karen Kelly, Philip C Mack, Hanna M. Saba, Mohamed K. Mohamed, David R. Gandara
Journal: Journal of Clinical Oncology (2012)

7005 Background: Topotecan (T) (oral and IV) is the only FDA-approved second-line chemotherapy for patients with SCLC. Weekly T is associated with less toxicity than the daily x 5 regimen. AVE0005 (aflibercept) (A) is a novel recombinant human fusion protein which binds to circulating VEGF, thereby inhibiting its interaction with cell surface receptors. We sought to evaluate the efficacy and toxicity of weekly IV T (4 mg/m2) with or without A (6 mg/kg Q21D) in patients with relapsed SCLC following one line of platinum-based chemotherapy for E or limited-stage (L) SCLC. Methods: Patients were randomized 1:1 to T or A+T. Eligible patients had adequate organ function, ECOG PS 0-1, and no recent bleeding or cardiac events. Patients with brain metastases stable for ≥ 3 months prior to study entry were allowed. Primary endpoint was 3-month PFS. Patients were stratified as platinum-sensitive (PS) or platinum-refractory (PR). PR patients had progressed within 90 days of last chemotherapy for E and 6 months for L. This report is limited to the PR stratum. Results: 98 patients were registered. 1 was ineligible and 1 withdrew consent, leaving 96 evaluable for the primary endpoint (91 for toxicity (see Table for characteristics)). 3-month PFS was 26% for A+T versus 9% for T (P=0.01). Overall survival was similar in each arm (4.6 mos (A+T) versus 3.9 mos (T) (P=0.25)). There was 1 partial response with A+T. Disease control rate (DCR) was 28% with A+T and 12% with T. Toxicity was mainly hematologic with 14% and 19% of patients experiencing a Grade 4 event with T and A+T, respectively. There was one treatment-related death with T (renal failure). Conclusions: This study met its primary endpoint of improved 3-month PFS with A+T (p=0.01), warranting further study in the PR setting. Clinical benefit with A+T was achieved primarily through improved DCR. Toxicity was manageable and less than is seen with standard dose T. Accrual to the PS cohort is ongoing. [Table: see text]
Erythrocytes and Platelets May Contribute to Hypercoagulability In Nephrotic Syndrome Through Enhanced Phosphatidylserine Exposure and Microparticles Release
Authors: Chunyan Gao, Rui Xie, Jing Wang, Chengyuan Yu, Xiaoyan Tan, Jianan Li, Rujuan Xie, Jin Zhou, Gary E. Gilbert, Jialan Shi
Journal: Blood (2011)
Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma
Authors: Satoshi Takagi, Shokichi Tsukamoto, Yawara Kawano, Michele Moschetta, Yuji Mishima, Katsutoshi Kokubun, Salomon Manier, Karma Salem, Daisy Huynh, Antonio Sacco, Aldo M Roccaro, Kelly Elizabeth Johnson, Elisabeth M. Battinelli, Irene M. Ghobrial
Journal: Blood (2015)
Why women are choosing mastectomy: Influences beyond the surgeon.
Authors: Andrea Marie Covelli, Nancy N. Baxter, Margaret Fitch, Frances Catriona Wright
Journal: Journal of Clinical Oncology (2014)

1094 Background: Rates of unilateral (UM) and contralateral prophylactic mastectomy (CPM) for early stage breast cancer (ESBC) have been increasing. Surgical decision making is comprised of the surgeon, the patient and the external environment. We sought the perspectives of patients who chose UM +/- CPM and treating surgeons to understand why mastectomy rates have been increasing. Methods: We completed a grounded theory qualitative study to examine the surgeon’s practice and the patient’s decision making that resulted in the choice for UM +/- CPM. Purposive sampling identified women across Toronto, Canada who were suitable candidates for breast conserving therapy (BCT) but underwent UM +/- CPM. Academic and community breast surgeons from across Ontario, Canada and the United States were also recruited. Data were collected through semi-structured interviews, this continued until data saturation was reached. Constant comparative analysis identified key ideas. Results: 29 patients and 45 surgeons completed interviews. The dominant theme was ‘Desire for control’, women strived to improve their cancer outcomes by undergoing more extensive surgery. Surgeons described BCT and UM as equivalent treatment options for ESBC and frequently recommended BCT. Despite this, surgeons described women initiating the request for UM+CPM. In this average risk population CPM was discouraged by the surgeons, describing no survival advantage. The most influential factor in a woman’s request for CPM was their personal cancer experiences with family and friends and not the surgical consultation. A previous negative experience with breast cancer translated into an overestimated risk of recurrence, contralateral cancerand subsequent mortality. Women chose UM+CPM to ensure they would ‘never go through this again.’ Despite feeling confident in their choice most women had ongoing issues with disturbed skin sensation, cosmesis and body image. Conclusions: Factors, especially a previous cancer experience, are extremely influential when women choose UM+/-CPM. As many women had long term pain and issues with cosmesis after UM +/- CPM, we suggest women may benefit from education including exposure to other patients’ post-operative concerns to aid in their decision making.
Palliative whole brain radiotherapy: Predictors of prescribing 5 versus 10 fractions.
Authors: Adele Duimering, Sarah Baker, Kim Paulson, Brock J Debenham, Sunita Ghosh, David L Ma, Fleur Huang, Karen P Chu, Diane Severin, John Amanie, Tirath Nijjar, Samir Patel, Ericka Wiebe, Brita Lavender Danielson, Bronwen LeGuerrier, Alysa M. Fairchild
Journal: Journal of Clinical Oncology (2016)

219 Background: The optimal dose for palliative whole brain radiotherapy (WBRT) continues to be debated. Common regimens include 20 Gy in five and 30 Gy in 10 fractions. We aimed to identify factors associated with WBRT dose schedules, hypothesizing that clinical prediction of survival (CPS) would influence prescribing practice. Methods: Demographic and clinicopathologic data were collected for consecutive patients with brain metastases receiving WBRT through a dedicated palliative radiation oncology clinic. At initial consultation, CPS were prospectively collected from treating radiation oncologists. Karnofsky performance status (KPS) and Mini-Mental Status Examination were available for 88.6% and 75.1%, respectively. Dose fractionation was collected and summary statistics calculated. Parameters were assessed for association with five fraction schedules using binary logistic regression, with odds ratios and 95% CI reported. Results: 193 patients underwent WBRT (N = 102 from 2010-2012; N = 91 from 2013-2014); 38/193 had 48 extracranial sites irradiated concurrently. 46.1% were male, mean age was 64.7 years (SD 11.6), and 63.7% had lung cancer. Median KPS was 70 (range 20-100) and median MMSE score was 27/30 (range 13-30). Median CPS and actual survival were 150 days (range 21-730d) and 96 days (range 11-1029d), respectively. 18.7% received WBRT within 30 days of death. 78.2% (151/193) and 17.6% (34/193) received five and 10 fractions, respectively; 8/193 were prescribed other schedules. On multivariate analysis, patients with KPS ≤ 70 were 5.93 times more likely to have received 5-fractions (95% CI 2.51-14.1; p &lt; 0.0001). Those treated 2010-2012 were less likely to have received 5 fractions (OR 0.28; 95% CI 0.11-0.68; p = 0.005). CPS, age, gender, MMSE, histology, disease extent, and extracranial irradiation were not predictive of WBRT schedule. Conclusions: Patients treated with WBRT with KPS ≤70 and those treated more recently were more likely to receive five fractions. Oncologist CPS was not a statistically significant predictor of schedule in this cohort.
Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients
Authors: G. Fountzilas, A. Psyrri, E. Giannoulatou, G. Kouvatseas, D. Rontogianni, E. Ciuleanu, T.-E. Ciuleanu, L. Resiga, T. Zaramboukas, M. Bobos, S. Chrisafi, E. Tsolaki, K. Papadopoulou, K. Markou, N. Charalambakis, A. Koutras, A. Kalogera-Fountzila, M. Skondra, D. Pectasides, V. Kotoula
Journal: Annals of Oncology (2016)
Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids
Authors: David Miklos, Corey S. Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, Aaron C. Logan, Ryotaro Nakamura, Bruce R. Blazar, Yunfeng Li, Indu Lal, Jason Dubovsky, Danelle F. James, Lori Styles, Samantha Jaglowski
Journal: Blood (2016)
Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
Authors: Asad Bashey, MeiJie Zhang, Shannon R. McCurdy, Stefan O. Ciurea, Andrew St. Martin, Claudio Anasetti, Trevor Argall, Omotayo O. Fasan, Sameh Gaballa, Mehdi Hamadani, Monzr M al Malki, Pashna N. Munshi, Ryotaro Nakamura, Paul V. O'Donnell, Miguel-Angel Perales, Kavita Raj, Vanderson Rocha, Rizwan Romee, Scott D. Rowley, Rachel Salit, Melhem Solh, Robert J. Soiffer, John R. Wingard, Daniel J. Weisdorf, Mary M Horowitz, Ephraim Joseph Fuchs, Mary Eapen
Journal: Blood (2016)
A Possible Mechanism for Synergy in Transcriptional Activation between AML1 and PU.1: Exclusion of the Co-Repressor CBFA2T3 (ETO-2, MTG16).
Authors: Kristine Baraoidan, Vinzon Ibanez, Chetna Mittal, Habte Yimer, Suman Chakraborty, Kisle Sinha, Steven Ackerman, Giuseppina Nucifora, Yogenthiran Saunthararajah
Journal: Blood (2004)
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study
Authors: Qing-Lei Zeng, Guang-Hua Xu, Ji-Yuan Zhang, Wei Li, Da-Wei Zhang, Zhi-Qin Li, Hong-Xia Liang, Chun-Xia Li, Zu-Jiang Yu
Journal: Journal of Hepatology (2017)